NCT02027376 2023-04-03
EDALINE
Spanish Breast Cancer Research Group
Phase 1 Completed
Clinical Trials
13 trialsNCT02086552 2021-12-03
Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma
Mayo Clinic
Phase 2 Completed
NCT01787552 2020-04-15
A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF
Novartis
Phase 1/2 Completed
NCT01431794 2020-01-22
Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Terminated
NCT01327053 2019-08-28
BOLT
Novartis
Phase 2 Completed
NCT02111187 2019-03-07
LDE225
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT02303041 2019-01-29
Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
Stanford University
Phase 2 Terminated
NCT01708174 2017-08-11
A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)
Novartis
Phase 2 Completed
NCT02254551 2017-02-16
Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT01529450 2017-01-16
Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors
Stanford University
Phase NA Completed
NCT01826214 2016-08-30
Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia
Novartis
Phase 2 Completed
NCT02002689 2016-05-02
SIGNATURE
Novartis
Phase 2 Terminated
NCT01350115 2015-10-19
Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)
Novartis
Phase 2 Completed